AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Imjudo (tremelimumab) — US product sales by Year
Imjudo (tremelimumab) — US product sales ($M) ($M)
AstraZeneca Imjudo (tremelimumab) — US product sales: $227M in FY2025, up 26.1% from a year earlier.
Where the FY2025 figure comes from
“|| Imjudo | 346 | 23 | 23 | 227 | 26 | 22 | 40 | 43 | 52 | 43 | 38 | 45 | (9) | (9)”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Imjudo (tremelimumab) — US product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 227 | +26.1% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 180 | – | Form 6-K FY2024Q4 Earnings Release ↗ |
Breakdown
What makes up imjudo (tremelimumab) — US product sales
Cite this data
StockData. (2026). AstraZeneca Imjudo (tremelimumab) — US product sales ($M), annual FY2024–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-imjudo-us
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.